Edison Scientific, a new venture spun off from AI scientist company FutureHouse, has secured $70 million in funding to revolutionize drug discovery through artificial intelligence. This move comes as major pharmaceutical companies increasingly seek advanced AI solutions to enhance their research capabilities, highlighting a growing trend in the industry towards integrating cutting-edge technology into traditional drug development processes.
The formation of Edison Scientific is a direct response to the demand from top-tier drugmakers, who have recognized the potential of AI agents to accelerate scientific discovery. Co-founders Sam Rodriques and Andrew White aim to provide a commercial product that empowers scientists with AI tools capable of independent reasoning, thereby streamlining the drug discovery pipeline. This shift underscores the necessity for biopharma professionals to adapt to technological advancements that could redefine their operational frameworks.
Continue to STAT+ to read the full story…
Get started today with Solo access →
